The group of Nanomedicine@FCT - created and developed by Dr. Pedro V Baptista in 2003 - in the field of biofunctionalization of nanoparticles with targeting and silencing moieties and their application in drug delivery and/or gene silencing, in the assessment of toxicology of nanoparticles in in vivo models, in the development of nanobiosensors and micro fluidic devices for diagnostic applications, and DNA/RNA biomolecular recognition studies. At the intersection of Molecular Genetics and Nanotechnology, we have focused our research on the use of noble metal nanoparticles (mainly gold and silver) for new diagnostics and therapeutics platforms.
Peptide coated gold nanoparticles for in vivo targeting of angiogenesis
The Nanomedicine@FCT Group demonstrated for the first time the combined effect of visible laser irradiation and peptide decorated gold nanoparticle system to control with spatial precision the formation of blood vessels in vivo. Also, the group has created a new vectorization platform based on gold nanoparticles for the targeted delivery of chemical compounds to tumors in vivo allowing for more than 90% reduction of tumor size [J. Control. Release (2017) 245: 52–61].
Laser enhanced activity of peptide coated gold nanoparticles for in vivo targeting of angiogenesis with spatial precision.
Startup Launch Nano4 Global
The Start-up - NANO4 Global - based on the research performed by the group has been launched and successfully awarded a SME Phase I and then a SME Phase 2 Grant (€2.2 Million) to take a nanodiagnostics platform to the global market.
- “RA Detect: One Platform-multiple biomarker detection of rheumatoid arthritis”, EC-H2020, Total funding: €433,175, Unit funding: €137,600, Pedro Baptista (PI).
- “TRACE: tracking and assessing the risk from antibiotic resistant genes using chip technology in surface water ecosystems”, EC-ERA-Net, Total funding: €1,4M, Unit funding: €149,000, Pedro Baptista (PI).
- “Cytotoxicity and photo-cytotoxicity of nitrosyl ruthenium anticancer drug in aqueous solution or incorporated in a drug delivery system. An innovative purpose for metal based drug”, FCT-MCTES and FAPESP, Total funding: €43,790, Unit funding: €43,790, Pedro Baptista (Collaborator).
- “Silence is golden (siAu) - silencing the silencers via multifunctional gold nanoconjugates towards cancer therapy”, FCT-MCTES, Total funding: €188,922, Unit funding: €188,922, Pedro Baptista (PI).
- “Lung Card - Point-of-care blood device for fast and reliable prediction of drug response in non- small-cell lung carcinoma patients from blood samples”, EC-H2020, Total funding: €1.4M, Unit funding: €260,400, Pedro Baptista (Collaborator - PI in Portugal).
Kourmentza, C; Araujo, D; Sevrin, C; Roma-Rodriques, C; Ferreira, JL; Freitas, F; Dionisio, M; Baptista, PV; Fernandes, AR; Grandfils, C; Reis, MAM. 2019. Occurrence of non-toxic bioemulsifiers during polyhydroxyalkanoate production by Pseudomonas strains valorizing crude glycerol by-product. BIORESOURCE TECHNOLOGY, 281, DOI: 10.1016/j.biortech.2019.02.066
Roma-Rodrigues, C; Mendes, R; Baptista, PV; Fernandes, AR. 2019. Targeting Tumor Microenvironment for Cancer Therapy. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 20, DOI: 10.3390/ijms20040840
Jesus, AR; Soromenho, MRC; Raposo, LR; Esperanca, JMSS; Baptista, PV; Fernandes, AR; Reis, PM. 2019. Enhancement of water solubility of poorly water-soluble drugs by new biocompatible N-acetyl amino acid N-alkyl cholinium-based ionic liquids. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 137, DOI: 10.1016/j.ejpb.2019.03.004
Vinhas, R; Lourenco, A; Santos, S; Ribeiro, P; Silva, M; de Sousa, AB; Baptista, PV; Fernandes, AR. 2018. A double Philadelphia chromosome-positive chronic myeloid leukemia patient, co-expressing P210(BCR-ABL1) and P195(BCR-ABL1) isoforms. ACTA HAEMATOLOGICA, 103, DOI: 10.3324/haematol.2018.192534
Svahn, N; Moro, AJ; Roma-Rodrigues, C; Puttreddy, R; Rissanen, K; Baptista, PV; Fernandes, AR; Lima, JC; Rodriguez, L. 2018. The Important Role of the Nuclearity, Rigidity, and Solubility of Phosphane Ligands in the Biological Activity of Gold(I) Complexes. CHEMISTRY-A EUROPEAN JOURNAL, 24, DOI: 10.1002/chem.201802547